BACKGROUND: Evidence about the efficacy of statin treatment among patients after percutaneous coronary intervention (PCI) is very limited. The rapid advancement in PCI technology and near universal use of adjunctive cardioprotective medications make it necessary to formally assess the effect of statin therapy on cardiac events after PCI. DESIGN: This was a multicenter prospective cohort study. METHODS: Patients who received stent implantation and survived to hospital discharge from the National Heart, Lung, and Blood Institute Dynamic Registry from 2004 to 2006 formed the study cohort. Patients with cardiogenic shock, in-hospital adverse events [including myocardial infarction and coronary artery bypass graft surgery (CABG)], liver disease, renal disease, alcoholism, or drug abuse were excluded. The occurrences of death, CABG, and repeat PCI, and repeat revascularization were collected over 1-year follow-up. RESULTS: Of the 3227 patients evaluated, 2737 (85%) were prescribed a statin at discharge. By 1-year follow-up, incident events were 98 deaths, 44 CABG, 290 repeat PCI procedures, and 328 repeat revascularizations. After propensity score adjustment, postdischarge statin therapy was associated with lower risks of death [hazard ratio (HR): 0.58, 95% confidence interval (CI): 0.36-0.93, P = 0.02], CABG (HR: 0.49, 95% CI: 0.24-1.00, P = 0.05), and repeat revascularization (HR: 0.74, 95% CI: 0.56-1.00, P = 0.05). CONCLUSION: These results support the routine use of statin therapy after PCI.
BACKGROUND: Evidence about the efficacy of statin treatment among patients after percutaneous coronary intervention (PCI) is very limited. The rapid advancement in PCI technology and near universal use of adjunctive cardioprotective medications make it necessary to formally assess the effect of statin therapy on cardiac events after PCI. DESIGN: This was a multicenter prospective cohort study. METHODS:Patients who received stent implantation and survived to hospital discharge from the National Heart, Lung, and Blood Institute Dynamic Registry from 2004 to 2006 formed the study cohort. Patients with cardiogenic shock, in-hospital adverse events [including myocardial infarction and coronary artery bypass graft surgery (CABG)], liver disease, renal disease, alcoholism, or drug abuse were excluded. The occurrences of death, CABG, and repeat PCI, and repeat revascularization were collected over 1-year follow-up. RESULTS: Of the 3227 patients evaluated, 2737 (85%) were prescribed a statin at discharge. By 1-year follow-up, incident events were 98 deaths, 44 CABG, 290 repeat PCI procedures, and 328 repeat revascularizations. After propensity score adjustment, postdischarge statin therapy was associated with lower risks of death [hazard ratio (HR): 0.58, 95% confidence interval (CI): 0.36-0.93, P = 0.02], CABG (HR: 0.49, 95% CI: 0.24-1.00, P = 0.05), and repeat revascularization (HR: 0.74, 95% CI: 0.56-1.00, P = 0.05). CONCLUSION: These results support the routine use of statin therapy after PCI.
Authors: Gulay S Guven; Enver Atalar; Bunyamin Yavuz; Yavuz Beyazit; Murat Kekilli; Alparslan Kilicarslan; Levent Sahiner; Gul Oz; Necla Ozer; Serdar Aksoyek; Ibrahim C Haznedaroglu; Tumay Sozen Journal: J Natl Med Assoc Date: 2006-04 Impact factor: 1.798
Authors: M Schartl; W Bocksch; D H Koschyk; W Voelker; K R Karsch; J Kreuzer; D Hausmann; S Beckmann; M Gross Journal: Circulation Date: 2001-07-24 Impact factor: 29.690
Authors: H J Mulder; E T Bal; J W Jukema; A H Zwinderman; M J Schalij; A J van Boven; A V Bruschke Journal: Am J Cardiol Date: 2000-10-01 Impact factor: 2.778
Authors: Albert W Chan; Deepak L Bhatt; Derek P Chew; Martin J Quinn; David J Moliterno; Eric J Topol; Stephen G Ellis Journal: Circulation Date: 2002-02-12 Impact factor: 29.690
Authors: Naveed Sattar; Heather M Murray; Alex McConnachie; Gerard J Blauw; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; Michael B Murphy; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp; James Shepherd Journal: Circulation Date: 2007-02-05 Impact factor: 29.690
Authors: Patrick W J C Serruys; Pim de Feyter; Carlos Macaya; Norbert Kokott; Jacques Puel; Matthias Vrolix; Angelo Branzi; Marcelo C Bertolami; Graham Jackson; Bradley Strauss; Bernhard Meier Journal: JAMA Date: 2002-06-26 Impact factor: 56.272
Authors: Zhi-Jiang Zhang; Oscar C Marroquin; Roslyn A Stone; Joel L Weissfeld; Suresh R Mulukutla; Faith Selzer; Kevin E Kip Journal: Am Heart J Date: 2010-11 Impact factor: 4.749